Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Affymetrix Up 17 Percent; UBS Upgrades Stock

NEW YORK (GenomeWeb News) — Shares in Affymetrix were up 17.74 percent, or $4.09, at $26.72 this afternoon after the company yesterday released its third-quarter earnings.
 
Today, investment bank UBS upgraded its rating of Affy shares to ‘Neutral’ from ‘Reduce.’
 
As GenomeWeb News reported yesterday, Affy said that third-quarter revenue increased around 1 percent as last year's profit swung to a loss.
The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.